tetano
Editor, Senior Moderator
Int J Infect Dis
. 2025 Nov 11:108205.
doi: 10.1016/j.ijid.2025.108205. Online ahead of print. Comparison of the immunogenicity of adjuvanted and conventional egg-based quadrivalent influenza vaccines among healthcare personnel in Lima, Peru: A randomized controlled trial
Perrine Marcenac[SUP] 1 [/SUP], Giselle Soto[SUP] 2 [/SUP], Tat Yau[SUP] 1 [/SUP], Joseph Daniel Carreon[SUP] 1 [/SUP], Candice Romero[SUP] 3 [/SUP], Miriam Gonzales[SUP] 3 [/SUP], Sayda La Rosa[SUP] 3 [/SUP], Carmen Sofia Arriola[SUP] 1 [/SUP], Michael Prouty[SUP] 2 [/SUP], Roger A Hernández Díaz[SUP] 4 [/SUP], Fiorela Alvarez Romero[SUP] 4 [/SUP], Alejandro Llanos-Cuentas[SUP] 4 [/SUP], Eduardo D Matos Prado[SUP] 5 [/SUP], Maria Silva[SUP] 2 [/SUP], Ashley Fowlkes[SUP] 1 [/SUP], Min Z Levine[SUP] 1 [/SUP], Eduardo Azziz-Baumgartner[SUP] 1 [/SUP], Lindsey M Duca[SUP] 6 [/SUP], Joan Neyra[SUP] 2 [/SUP]
Affiliations
Objectives: We conducted a randomized controlled trial to evaluate whether adjuvanted quadrivalent inactivated influenza vaccine (aIIV4) generates superior immunogenicity against influenza viruses compared to conventional quadrivalent inactivated influenza vaccine (IIV4) among healthcare personnel (HCP) in Lima, Peru.
Methods: During 2022‒2023, we randomized 192 HCP aged ≥18 years to receive 2022 Southern Hemisphere IIV4 or aIIV4 and collected pre-, one-month post-, and six-months post-vaccination sera. Geometric mean titers (GMTs), GMT ratios, seroconversion rates (SCR), and seroprotection rates (SPR) were compared against vaccine reference viruses-influenza A(H1N1)pdm09, A(H3N2), B/Victoria, and B/Yamagata-using hemagglutination inhibition assays.
Results: Most HCP (77‒99%) had titers ≥40 following vaccination. One-month post-vaccination, aIIV4 induced higher GMTs (GMT ratio: 1.7 [95% CI 1.1‒2.7]) and SCR (88.4% [80.4‒93.4] vs. 62.1% [52.1‒71.2]) against A(H1N1)pdm09 and higher SCR (82.1% [73.2‒88.5] vs. 62.1% [52.1‒71.2]) against A(H3N2) compared to IIV4. At six months, aIIV4 induced higher SPR against A(H3N2) (90.4% [82.8‒94.9] vs. 74.0% [64.4‒81.7]) than IIV4. IIV4 recipients vaccinated the preceding influenza season had lower odds of seroconverting to A(H1N1)pdm09 compared to IIV4 recipients who were not vaccinated (aOR: 0.29 [0.13‒0.63], p=0.002).
Conclusion: These findings provide insights into the benefits of an enhanced influenza vaccine (aIIV4) to help overcome the immune blunting effects of repeat vaccination among HCP.
Keywords: healthcare personnel; influenza; vaccination.
. 2025 Nov 11:108205.
doi: 10.1016/j.ijid.2025.108205. Online ahead of print. Comparison of the immunogenicity of adjuvanted and conventional egg-based quadrivalent influenza vaccines among healthcare personnel in Lima, Peru: A randomized controlled trial
Perrine Marcenac[SUP] 1 [/SUP], Giselle Soto[SUP] 2 [/SUP], Tat Yau[SUP] 1 [/SUP], Joseph Daniel Carreon[SUP] 1 [/SUP], Candice Romero[SUP] 3 [/SUP], Miriam Gonzales[SUP] 3 [/SUP], Sayda La Rosa[SUP] 3 [/SUP], Carmen Sofia Arriola[SUP] 1 [/SUP], Michael Prouty[SUP] 2 [/SUP], Roger A Hernández Díaz[SUP] 4 [/SUP], Fiorela Alvarez Romero[SUP] 4 [/SUP], Alejandro Llanos-Cuentas[SUP] 4 [/SUP], Eduardo D Matos Prado[SUP] 5 [/SUP], Maria Silva[SUP] 2 [/SUP], Ashley Fowlkes[SUP] 1 [/SUP], Min Z Levine[SUP] 1 [/SUP], Eduardo Azziz-Baumgartner[SUP] 1 [/SUP], Lindsey M Duca[SUP] 6 [/SUP], Joan Neyra[SUP] 2 [/SUP]
Affiliations
- PMID: 41232749
- DOI: 10.1016/j.ijid.2025.108205
Objectives: We conducted a randomized controlled trial to evaluate whether adjuvanted quadrivalent inactivated influenza vaccine (aIIV4) generates superior immunogenicity against influenza viruses compared to conventional quadrivalent inactivated influenza vaccine (IIV4) among healthcare personnel (HCP) in Lima, Peru.
Methods: During 2022‒2023, we randomized 192 HCP aged ≥18 years to receive 2022 Southern Hemisphere IIV4 or aIIV4 and collected pre-, one-month post-, and six-months post-vaccination sera. Geometric mean titers (GMTs), GMT ratios, seroconversion rates (SCR), and seroprotection rates (SPR) were compared against vaccine reference viruses-influenza A(H1N1)pdm09, A(H3N2), B/Victoria, and B/Yamagata-using hemagglutination inhibition assays.
Results: Most HCP (77‒99%) had titers ≥40 following vaccination. One-month post-vaccination, aIIV4 induced higher GMTs (GMT ratio: 1.7 [95% CI 1.1‒2.7]) and SCR (88.4% [80.4‒93.4] vs. 62.1% [52.1‒71.2]) against A(H1N1)pdm09 and higher SCR (82.1% [73.2‒88.5] vs. 62.1% [52.1‒71.2]) against A(H3N2) compared to IIV4. At six months, aIIV4 induced higher SPR against A(H3N2) (90.4% [82.8‒94.9] vs. 74.0% [64.4‒81.7]) than IIV4. IIV4 recipients vaccinated the preceding influenza season had lower odds of seroconverting to A(H1N1)pdm09 compared to IIV4 recipients who were not vaccinated (aOR: 0.29 [0.13‒0.63], p=0.002).
Conclusion: These findings provide insights into the benefits of an enhanced influenza vaccine (aIIV4) to help overcome the immune blunting effects of repeat vaccination among HCP.
Keywords: healthcare personnel; influenza; vaccination.